Si-Ning Liu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5626868/publications.pdf

Version: 2024-02-01

266	6,742	101543	88630
papers	citations	36 h-index	70 g-index

292	292	292	4378
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood, 2006, 107, 3065-3073.	1.4	482
2	Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood, 2015, 125, 3956-3962.	1.4	387
3	Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood, 2014, 124, 843-850.	1.4	285
4	Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 257-265.	2.0	278
5	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood, 2013, 121, 4056-4062.	1.4	277
6	Risk stratificationâ€“directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood, 2012, 119, 3256-3262.	1.4	264
7	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in Chinaâ€”recommendations from the Chinese Society of Hematology. Journal of Hematology and Oncology, 2018, 11, 33.	17.0	233
8	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematology and Oncology, 2015, 8, 84.	17.0	160
9	Superior Graft-versus-Leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison. Biology of Blood and Marrow Transplantation, 2011, 17, 821-830.	2.0	149
10	Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica, 2007, 92, 414-417.	3.5	147
11	Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. Clinical Cancer Research, 2016, 22, 3467-3476.	7.0	142
12	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. Journal of Hematology and Oncology, 2017, 10, 134.	17.0	132
13	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. Journal of Clinical Oncology, 2016, 34, 1855-1863.	1.6	100
14	Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Annals of Hematology, 2013, 92, 1111-1119.	1.8	87
15	Donorâ€derived <scp>CD</scp>19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2017, 179, 598-605.	2.5	87
16	Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. Journal of Hematology and Oncology, 2019, 12, 88.	17.0	76
17	Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood, 2016, 128, 2988-2999.	1.4	73
18	Mitochondrial Reactive Oxygen Species Regulate Adipocyte Differentiation of Mesenchymal Stem Cells in Hematopoietic Stress Induced by Arabinosylcytosine. PLoS ONE, 2015, 10, e0120629.	2.5	67

#	Article	IF	Citations
19	Coinfusion of Mesenchymal Stromal Cells Facilitates Platelet Recovery Without Increasing Leukemia Recurrence in Haploidentical Hematopoietic Stem Cell Transplantation: A Randomized, Controlled Clinical Study. Stem Cells and Development, 2011, 20, 1679-1685.	2.1	64
20	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Longâ€term outcomes of a prospective randomized trial. Cancer, 2017, 123, 2881-2892.	4.1	63
21	Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression. Stem Cells Translational Medicine, 2016, 5, 1631-1643.	3.3	57
22	Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. Journal of Hematology and Oncology, 2016, 9, 87.	17.0	57
23	Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro <scp>T</scp>â€cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. European Journal of Haematology, 2013, 91, 304-314.	2.2	55
24	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 44.	17.0	51
25	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. American Journal of Hematology, 2019, 94, 512-521.	4.1	51
26	Human Bone Marrow Mesenchymal Stem Cells Rescue Endothelial Cells Experiencing Chemotherapy Stress by Mitochondrial Transfer Via Tunneling Nanotubes. Stem Cells and Development, 2019, 28, 674-682.	2.1	48
27	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. Journal of Hematology and Oncology, 2020, 13, 27.	17.0	48
28	Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget, 2016, 7, 30892-30906.	1.8	48
29	Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with highâ€risk acute lymphoblastic leukemia. International Journal of Cancer, 2016, 139, 2106-2115.	5.1	47
30	Epstein-Barr Virusâ€"Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. Biology of Blood and Marrow Transplantation, 2015, 21, 2185-2191.	2.0	46
31	Haploidentical Hematopoietic Stem Cell Transplantation without InÂVitro T Cell Depletion for the Treatment of Philadelphia Chromosomeâ€"Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1110-1116.	2.0	44
32	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Advances, 2019, 3, 1303-1317.	5.2	43
33	Recipient expression of ligands for donor inhibitory KIRs enhances NKâ€cell function to control leukemic relapse after haploidentical transplantation. European Journal of Immunology, 2015, 45, 2396-2408.	2.9	42
34	Haploidentical hematopoietic stem cell transplantation in adults with Philadelphiaâ€negative acute lymphoblastic leukemia: No difference in the highâ€and lowâ€risk groups. International Journal of Cancer, 2015, 136, 1697-1707.	5.1	42
35	IFN-Î± Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. Biology of Blood and Marrow Transplantation, 2017, 23, 1303-1310.	2.0	40
36	The effect of HLA disparity on clinical outcome after HLAâ€haploidentical blood and marrow transplantation. Clinical Transplantation, 2012, 26, 284-291.	1.6	39

#	Article	IF	Citations
37	Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 829-838.	1.8	39
38	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematology,the, 2017, 4, e487-e496.	4.6	38
39	Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1310-1318.	2.4	38
40	Salvage chemotherapy followed by granulocyte colonyâ€stimulating factorâ€primed donor leukocyte infusion with graftâ€vs.â€host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. European Journal of Haematology, 2016, 96, 297-308.	2.2	37
41	Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1314-1321.	2.0	36
42	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. Stem Cells and Development, 2017, 26, 1648-1661.	2.1	36
43	Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 741-750.	2.0	36
44	Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation. Clinical Infectious Diseases, 2018, 67, S162-S173.	5.8	36
45	Early myeloid-derived suppressor cells (HLA-DRâ¯/lowCD33+CD16â¯) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. Journal of Hematology and Oncology, 2019, 12, 31.	17.0	35
46	Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. Journal of Hematology and Oncology, 2015, 8, 116.	17.0	34
47	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2020, 22, 755-761.	0.7	33
48	Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the <scp>TNFAIP</scp>3/<scp>NF</scp>â€ºB/<scp>SMAD</scp> pathway in patients with immune thrombocytopenia. British Journal of Haematology, 2018, 180, 395-411.	2.5	32
49	Prognostic factors and longâ€term followâ€up of basiliximab for steroidâ€refractory acute <scp>graftâ€versusâ€host disease</scp>: Updated experience from a largeâ€scale study. American Journal of Hematology, 2020, 95, 927-936.	4.1	32
50	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leukemia and Lymphoma, 2015, 56, 3116-3123.	1.3	31
51	Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. BMC Cancer, 2016, 16, 269.	2.6	31
52	Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Biology of Blood and Marrow Transplantation, 2019, 25, 1611-1620.	2.0	30
53	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)â€“specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 70, 1429-1437.	5.8	30
54	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemiaâ€“Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 929-936.	2.0	28

#	Article	IF	Citations
55	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. OncoImmunology, 2017, 6, e1356152.	4.6	28
56	Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1637-1643.	1.8	27
57	The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Science Bulletin, 2018, 63, 1376-1382.	9.0	27
58	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Advances, 2019, 3, 4312-4325.	5.2	27
59	Monitoring of postâ€transplant <scp>CBFB</scp>â€<scp>MYH</scp>11 as minimal residual disease, rather than <scp>KIT</scp> mutations, can predict relapseÂafter allogeneic haematopoietic cell transplantation inÂadults with inv(16) acute myeloid leukaemia. British Journal of Haematology, 2018, 180, 448-451.	2.5	26
60	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clinical Cancer Research, 2019, 25, 1737-1748.	7.0	26
61	Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1936-1943.	2.0	25
62	T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clinical Immunology, 2018, 190, 32-40.	3.2	24
63	Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. Journal of Hematology and Oncology, 2019, 12, 87.	17.0	24
64	Cysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. Oncotarget, 2017, 8, 35984-36000.	1.8	23
65	Viral encephalitis after haploâ€identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. European Journal of Haematology, 2017, 98, 450-458.	2.2	22
66	Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study. Stem Cells International, 2018, 2018, 1-9.	2.5	22
67	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. Leukemia, 2021, 35, 3092-3100.	7.2	22
68	Total Body Irradiation and Cyclophosphamide Plus Antithymocyte Globulin Regimen Is Well Tolerated and Promotes Stable Engraftment as a Preparative Regimen before T Cellâ€“Replete Haploidentical Transplantation for Acute Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1176-1182.	2.0	21
69	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. OncoImmunology, 2016, 5, e1250992.	4.6	21
70	Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. Journal of Clinical Virology, 2016, 75, 10-15.	3.1	21
71	Recipientâ€donor KIR ligand matching prevents CMV reactivation postâ€haploidentical T cellâ€replete transplantation. British Journal of Haematology, 2017, 177, 766-781.	2.5	21
72	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). Blood Cancer Journal, 2018, 8, 76.	6.2	21

#	Article	IF	Citations
73	Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. BMC Cancer, 2020, 20, 553.	2.6	21
74	Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 620891.	4.8	21
75	Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100Âdays after allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1877-1883.	1.8	20
76	Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. Journal of Infection, 2016, 73, 261-270.	3.3	19
77	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 2143-2150.	2.0	19
78	Rosiglitazone Promotes Bone Marrow Adipogenesis to Impair Myelopoiesis under Stress. PLoS ONE, 2016, 11, e0149543.	2.5	19
79	A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Experimental Hematology and Oncology, 2022, 11, 25.	5.0	19
80	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyteâ€“colonyâ€stimulating factorâ€“mobilized marrow harvests and peripheral blood harvests. Transfusion, 2015, 55, 2874-2881.	1.6	18
81	Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis. Bone Marrow Transplantation, 2018, 53, 770-773.	2.4	18
82	Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia. Blood Advances, 2019, 3, 1416-1428.	5.2	18
83	Interferon-Î± salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 238-249.	3.4	18
84	The Quantification of Minimal Residual Disease Preâ€•and Postâ€Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 75-87.	1.5	18
85	Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fmsâ€like tyrosine kinase 3 internal tandem duplication (FLT3â€ITD). British Journal of Haematology, 2020, 190, 274-283.	2.5	18
86	Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1147-1160.	2.4	18
87	An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood, 2022, 140, 516-520.	1.4	18
88	Interferon-Î± Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. Oncologist, 2018, 23, 1349-1357.	3.7	17
89	Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as postâ€remission treatment for children with very highâ€risk philadelphia chromosome negative Bâ€cell acute lymphoblastic leukaemia in first complete remission. British Journal of Haematology, 2020, 188, 757-767.	2.5	17
90	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. Frontiers in Oncology, 2020, 10, 320.	2.8	17

#	Article	IF	Citations
91	Lowâ€dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical <scp>HSCT</scp>. Clinical Transplantation, 2015, 29, 594-605.	1.6	16
92	Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors. Transfusion, 2015, 55, 2023-2031.	1.6	16
93	Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1080-1086.	2.0	16
94	Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1233-1240.	1.8	16
95	Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Science China Life Sciences, 2019, 62, 691-697.	4.9	16
96	Autologous cord blood cell infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications. Stem Cells Translational Medicine, 2020, 9, 169-176.	3.3	16
97	Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. Chinese Medical Journal, 2014, 127, 3602-9.	2.3	16
98	Adiponectin receptor agonist AdipoRon suppresses adipogenesis in C3H10T1/2 cells through the adenosine monophosphate-activated protein kinase signaling pathway. Molecular Medicine Reports, 2017, 16, 7163-7169.	2.4	15
99	Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. Functional and Integrative Genomics, 2018, 18, 287-299.	3.5	15
100	Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cellular and Molecular Immunology, 2022, 19, 482-491.	10.5	15
101	Haploidentical stem cell transplantation in patients aged 50Âyr and older with leukemia: similar outcomes compared to younger adults. Clinical Transplantation, 2015, 29, 523-530.	1.6	14
102	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Annals of Hematology, 2018, 97, 485-495.	1.8	14
103	Detection of measurable residual disease may better predict outcomes than mutations based on nextâ€generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. British Journal of Haematology, 2020, 190, 533-544.	2.5	14
104	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Annals of Hematology, 2021, 100, 169-180.	1.8	14
105	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia, 2022, 36, 267-270.	7.2	14
106	Interferon-Î± as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 2949-2956.	1.3	14
107	Adoptive therapy with <scp>cytomegalovirus</scp>â€specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy. American Journal of Hematology, 2022, 97, 762-769.	4.1	14
108	Thrombotic microangiopathy with concomitant <scp>GI</scp> aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. European Journal of Haematology, 2018, 100, 171-181.	2.2	13

#	Article	IF	Citations
109	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2659-2670.	1.8	13
110	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. Journal of Hematology and Oncology, 2020, 13, 52.	17.0	13
111	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. Frontiers in Medicine, 2021, 8, 604085.	2.6	13
112	Preemptive Interferon-Î± Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Frontiers in Immunology, 2022, 13, 757002.	4.8	13
113	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Letters, 2019, 442, 193-201.	7.2	12
114	Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. Bone Marrow Transplantation, 2019, 54, 1198-1207.	2.4	12
115	The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clinical Transplantation, 2021, 35, e14160.	1.6	12
116	Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. Frontiers in Immunology, 2021, 12, 749266.	4.8	12
117	Intracranial Hemorrhage and Mortality In 1461 Patients After Allogeneic Hematopoietic Stem Cell Transplantation For 6-Year Follow-Up: Study Of 44 Cases. Blood, 2013, 122, 3322-3322.	1.4	12
118	Infusionâ€related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graftâ€versusâ€host disease. Pediatric Transplantation, 2015, 19, 918-924.	1.0	11
119	Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. Clinical Transplantation, 2016, 30, 994-1001.	1.6	11
120	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. Biology of Blood and Marrow Transplantation, 2016, 22, 2235-2242.	2.0	11
121	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chinese Journal of Cancer, 2016, 35, 46.	4.9	11
122	Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution. Clinical Transplantation, 2016, 30, 170-178.	1.6	11
123	Acute kidney injury following haplo stem cell transplantation: incidence, risk factors and outcome. Bone Marrow Transplantation, 2018, 53, 483-486.	2.4	11
124	Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplantation, 2020, 55, 2035-2042.	2.4	11
125	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 190, 67-78.	2.5	11
126	Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia Research, 2020, 91, 106333.	0.8	11

#	Article	IF	Citations
127	The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. Molecular Cancer, 2014, 13, 25.	19.2	10
128	Risk factors for herpes simplex virus-1/2 viremia and clinical outcomes following unmanipulated haploidentical haematopoietic stem cell transplantation. Journal of Clinical Virology, 2017, 95, 20-25.	3.1	10
129	Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. Annals of Hematology, 2018, 97, 1209-1217.	1.8	10
130	A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. Platelets, 2019, 30, 994-1000.	2.3	10
131	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. Annals of Hematology, 2021, 100, 1203-1212.	1.8	10
132	Diminished expression of Î²2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. Annals of Hematology, 2018, 97, 641-654.	1.8	9
133	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 600-608.	2.4	9
134	FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplantation, 2019, 54, 1462-1470.	2.4	9
135	Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1203-1209.	2.0	9
136	The Prognostic Significance of ZNF384 Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center. Frontiers in Oncology, 2021, 11, 632532.	2.8	9
137	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2097-2107.	2.4	9
138	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 67.	6.2	9
139	Haploidentical hematopoietic stem cell transplantation for paediatric highâ€risk <scp>T</scp>â€cell acute lymphoblastic leukaemia. Pediatric Transplantation, 2016, 20, 572-580.	1.0	8
140	High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation. European Journal of Haematology, 2016, 96, 517-526.	2.2	8
141	Increased prostacyclin levels inhibit the aggregation and activation of platelets via the PI3Kâ€“AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 139, 1-9.	1.7	8
142	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leukemia and Lymphoma, 2016, 57, 2133-2139.	1.3	8
143	A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics, and Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 1158-1164.	2.0	8
144	Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. Leukemia Research, 2017, 59, 136-141.	0.8	8

#	Article	IF	Citations
145	Utility of flexible bronchoscopy with polymerase chain reaction in the diagnosis and management of pulmonary infiltrates in allogeneic <scp>HSCT</scp> patients. Clinical Transplantation, 2018, 32, e13146.	1.6	8
146	The prognostic significance of Wilmsâ€™ tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia. Annals of Hematology, 2019, 98, 2551-2559.	1.8	8
147	Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 354-364.	3.4	8
148	Improved survival after offspring donor transplant compared with older agedâ€matched siblings for older leukaemia patients. British Journal of Haematology, 2020, 189, 153-161.	2.5	8
149	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1171-1178.	2.0	8
150	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 2087-2097.	2.4	8
151	Haploidentical stem cell transplantation in patients with chronic myelomonocytic leukemia. Science China Life Sciences, 2020, 63, 1261-1264.	4.9	8
152	G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study. Frontiers in Oncology, 2021, 11, 631625.	2.8	8
153	Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models. Bone Marrow Transplantation, 2021, 56, 1341-1351.	2.4	8
154	Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation. Therapeutic Advances in Hematology, 2022, 13, 204062072110728.	2.5	8
155	Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation. JCI Insight, 2022, 7, .	5.0	8
156	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Oncology, 2021, 11, 773394.	2.8	8
157	Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial. BMC Medicine, 2022, 20, 140.	5.5	8
158	Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. Leukemia Research, 2016, 47, 8-15.	0.8	7
159	Helicobacter pyloriinfection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets, 2016, 27, 223-229.	2.3	7
160	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Chinese Medical Journal, 2018, 131, 2808-2816.	2.3	7
161	High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. Cancer Medicine, 2019, 8, 5459-5467.	2.8	7
162	S100A16 suppresses the growth and survival of leukaemia cellsÂand correlates with relapse and relapse free survival in adults with Philadelphia chromosomeâ€negative Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 836-851.	2.5	7

#	Article	IF	Citations
163	Preemptive interferon-Î± treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. Scientific Reports, 2020, 10, 20148.	3.3	7
164	Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 20-20.	1.4	7
165	A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2022, 12, 862526.	3.9	7
166	Stromal-derived factor-1 deficiency in the bone marrow of acute myeloid leukemia. International Journal of Hematology, 2011, 93, 750-759.	1.6	6
167	IgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. Annals of Hematology, 2018, 97, 1399-1406.	1.8	6
168	Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 163-168.	2.0	6
169	Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children. Science China Life Sciences, 2019, 62, 104-111.	4.9	6
170	MAGE genes: Prognostic indicators in AL amyloidosis patients. Journal of Cellular and Molecular Medicine, 2019, 23, 5672-5678.	3.6	6
171	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1733-1742.	1.8	6
172	Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1629-1636.	2.0	6
173	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Advances, 2021, 5, 5479-5489.	5.2	6
174	CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clinical and Experimental Immunology, 2022, 208, 332-339.	2.6	6
175	High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 144, 6-11.	1.7	5
176	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia. Chinese Medical Journal, 2018, 131, 2185-2192.	2.3	5
177	Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 492-503.	3.4	5
178	Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. Pediatric Transplantation, 2020, 24, e13864.	1.0	5
179	Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection. Advances in Therapy, 2020, 37, 2493-2506.	2.9	5
180	Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graftâ€versusâ€host disease. Transplant Infectious Disease, 2021, 23, e13544.	1.7	5

#	Article	IF	Citations
181	Preâ€transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. Cancer Communications, 2021, 41, 333-344.	9.2	5
182	Wilmsâ€™ tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. BMC Cancer, 2021, 21, 292.	2.6	5
183	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. American Journal of Hematology, 2021, 96, 1407-1419.	4.1	5
184	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. Annals of Hematology, 2021, 100, 555-562.	1.8	5
185	Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transplantation, 2022, , .	2.4	5
186	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.8	5
187	Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study. Therapeutic Advances in Hematology, 2022, 13, 204062072210952.	2.5	5
188	Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplantation, 2022, 57, 1204-1206.	2.4	5
189	Higher dose of <scp>CD</scp>34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. Clinical Transplantation, 2017, 31, e12880.	1.6	4
190	Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2018, 53, 507-510.	2.4	4
191	Occurrence and Severity of Donor Lymphocyte Infusionâ€“Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 912-920.	2.0	4
192	Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation. Science China Life Sciences, 2020, 63, 138-147.	4.9	4
193	Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2020, 22, 188-195.	2.8	4
194	Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. Frontiers in Oncology, 2021, 11, 639502.	2.8	4
195	Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. Annals of Hematology, 2021, 100, 2557-2566.	1.8	4
196	Donor activating killer cell immunoglobulinâ€like receptors genes correlated with Epsteinâ€“Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2022, 196, 1007-1017.	2.5	4
197	Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. Frontiers in Immunology, 2021, 12, 731435.	4.8	4
198	Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study. Advances in Therapy, 2018, 35, 1400-1410.	2.9	3

#	Article	IF	Citations
199	Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 1833-1843.	1.8	3
200	A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. Chinese Medical Journal, 2021, 134, 1199-1208.	2.3	3
201	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2021, 100, 1267-1281.	1.8	3
202	Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia. Current Medical Science, 2021, 41, 443-453.	1.8	3
203	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model. Frontiers in Oncology, 2021, 11, 706935.	2.8	3
204	Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 668.e1-668.e9.	1.2	3
205	Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. Annals of Hematology, 2020, 99, 1643-1653.	1.8	3
206	Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	3
207	Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial. Chinese Medical Journal, 2010, 123, 2199-205.	2.3	3
208	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 814334.	4.8	3
209	Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment. Frontiers in Immunology, 0, 13, .	4.8	3
210	Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation. Journal of Thoracic Disease, 2016, 8, 2219-2225.	1.4	2
211	Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. Frontiers of Medicine, 2019, 13, 667-679.	3.4	2
212	Reduced Î²2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. Science China Life Sciences, 2019, 62, 921-929.	4.9	2
213	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, 1210-1217.	2.0	2
214	Both Methylation and Copy Number Variation Participated in the Varied Expression of PRAME in Multiple Myeloma . OncoTargets and Therapy, 2020, Volume 13, 7545-7553.	2.0	2
215	Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation. Thrombosis Research, 2020, 194, 168-175.	1.7	2
216	A retrospective analysis on anti-CD20 antibodyâ€“treated Epsteinâ€“Barr virusâ€“related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2649-2657.	1.8	2

#	Article	IF	Citations
217	Osteoclast stimulatory transmembrane protein (OCâ€STAMP) is a promising molecular prognostic indicator for multiple myeloma. European Journal of Haematology, 2020, 105, 185-195.	2.2	2
218	Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. Annals of Hematology, 2021, 100, 799-808.	1.8	2
219	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2022, 22, 11.	2.6	2
220	Combination of KIT and FLT3â€ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Hematological Oncology, 2022, 40, 724-733.	1.7	2
221	Association between C-reactive protein levels in the first 1â€“3 days post-transplant and allogeneic immune reactions. Biomarkers in Medicine, 2017, 11, 117-124.	1.4	1
222	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. Science China Life Sciences, 2018, 61, 924-933.	4.9	1
223	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1866-1872.	2.0	1
224	HCMV modulates câ€Mpl/IEXâ€1 pathwayâ€mediated megakaryo/thrombopoiesis via PDGFRÎ± and Î±vÎ²3 receptors after alloâ€HSCT. Journal of Cellular Physiology, 2021, 236, 6726-6741.	4.1	1
225	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. Transplantation and Cellular Therapy, 2021, 27, 253.e1-253.e9.	1.2	1
226	Low EVI1 expression at diagnosis predicted poor outcomes in pediatric Ph-negative B cell precursor acute lymphoblastic leukemia patients. Pediatric Hematology and Oncology, 2022, 39, 97-107.	0.8	1
227	ATRA Could Correct the Defective S1P-Mediated Cytoskeletal Reorganization in Proplatelet Formation of ITP. Blood, 2019, 134, 218-218.	1.4	1
228	CD4 + CD25 - CD69 + t Cells Is a Novel Subset of Regulatory T Cells Involved In the Prevention of Acute Graft-Versus-Host Disease In Human. Blood, 2010, 116, 1250-1250.	1.4	1
229	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience. Blood, 2016, 128, 2308-2308.	1.4	1
230	Optimal Dose of Antithymocyte Globulin in Conditioning Regimens for Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: Long-Term Outcomes of a Prospective Randomised Trial. Blood, 2016, 128, 3433-3433.	1.4	1
231	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget, 2017, 8, 41620-41630.	1.8	1
232	Machine-Learning Model for Resistance/Relapse Prediction in Immune Thrombocytopenia Using Gut Microbiota and Function Signatures. Blood, 2021, 138, 18-18.	1.4	1
233	PGE2 Dependent Inhibition of Macrophage Pyroptosis By MSCs Contributes to Alleviating aGVHD. Blood, 2020, 136, 15-15.	1.4	1
234	Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections. Advances in Therapy, 2022, 39, 1697-1710.	2.9	1

#	Article	IF	Citations
235	The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents. Pediatric Blood and Cancer, 2022, 69, .	1.5	1
236	Comments on the article: â€˜Donorâ€derived <scp>CD</scp>19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantationâ€™â€• Response to Pan etÂal. British Journal of Haematology, 2019, 184, 882-883.	2.5	0
237	Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion. Frontiers of Medicine, 2021, 15, 728-739.	3.4	0
238	Subclinical Alterations in Coagulation in Patients during Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 5292-5292.	1.4	0
239	HLA Mismatched/Haploidentical Haematopoietic Stem Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia.. Blood, 2006, 108, 3154-3154.	1.4	0
240	Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up. Blood, 2010, 116, 2347-2347.	1.4	0
241	Comparable Immune Reconstitution Achieved Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation and HLA-Identical Sibling Transplantation. Blood, 2010, 116, 2312-2312.	1.4	0
242	Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Association with Reduced Ploidy and Immaturation of Megakaryocytes. Blood, 2010, 116, 4695-4695.	1.4	0
243	IL-17-Producing T Cells Contribute to Mediate Acutegraft-Versus-Disease In Patients Undergoing Unmanipulated Blood and MarrowTransplantation. Blood, 2010, 116, 2310-2310.	1.4	0
244	Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,. Blood, 2011, 118, 4161-4161.	1.4	0
245	Leukemia Initiating Cells: New Markers for Minimal Residual Disease Monitoring in B-Precursor Acute Lymphoblastic Leukemia. Blood, 2011, 118, 2528-2528.	1.4	0
246	Pre-Emptive Therapy with Modified Donor Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 659-659.	1.4	0
247	A Clinical Study On Rituximab for Probable and Proven EBV Disease Post Haematopoietic Stem-Cell Transplantation. Blood, 2012, 120, 4512-4512.	1.4	0
248	Comparative Survival of Haploidentical and Matched Related Hematopoietic Stem Cell Transplantation for Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. Blood, 2014, 124, 2591-2591.	1.4	0
249	Risk-Stratification Directed Prophylaxis with Additional Low-Dose of Methylprednisolone Can Reduce Acute Graft-Versus-Host Disease for Patients with Hematological Malignancies after Allogeneic SCT: A Randomized, Controlled, Clinical Trial. Blood, 2014, 124, 40-40.	1.4	0
250	Long-Term Treatment with Rosiglitazone Delays Hematopoietic Recovery in Response to Stress. Blood, 2015, 126, 4769-4769.	1.4	0
251	Haploidentical Stem Cell Transplantation for Rare Pediatric Diseases at Peking University People's Hospital. Blood, 2016, 128, 5848-5848.	1.4	0
252	Polymorphisms of CTLA-4 Are Associated with Treatment Outcome in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens. Blood, 2016, 128, 3323-3323.	1.4	0

#	Article	IF	Citations
253	ADAM28 Enhanced the Growth and Dissemination of AML and Identified a Subgroup of AML Patients with a High Risk of Relapse in a Prospective Clinical Study. Blood, 2016, 128, 2902-2902.	1.4	0
254	Association Between C-Reactive Protein in the First 1-3 Days Post-Transplant and Allogeneic Immune Reactions in Pediatric Haploidentical Stem Cell Transplantation. Blood, 2016, 128, 5794-5794.	1.4	0
255	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Blood, 2018, 132, 3463-3463.	1.4	0
256	Haplo-SCT Mediates Stronger GVL Effect Than HLA-Matched Sibling Allograft By Significantly Reducing Leukemia Burden. Blood, 2018, 132, 2186-2186.	1.4	0
257	First-Line Therapy with Donor Derived HCMV-Specific T Cells Reduce Persistent HCMV Infection after Allogenic Stem Cell Transplantation. Blood, 2018, 132, 727-727.	1.4	0
258	Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?. Blood, 2018, 132, 2813-2813.	1.4	0
259	Poor NKG2C+ Adaptive NK Cell Recovery at Early Stage after Allo-HSCT Increased the Occurrence of Refractory Cytomegalovirus Infection. Blood, 2018, 132, 360-360.	1.4	0
260	Haploidentical Hematopoietic Stem Cell Transplantation May Improve Prognosis in Non-Infant Children with t(v;11q23)/MLL-Rearranged B-Acute Lymphoblastic Leukemia. Blood, 2019, 134, 2049-2049.	1.4	0
261	Treatment Outcome and Efficacy of Therapeutic Plasma Exchange for Transplant-Associated Thrombotic Microangiopathy in a Real-World Large Cohort Study. Blood, 2021, 138, 1013-1013.	1.4	0
262	Detection of CSRP2 Transcript Levels By Real-Time Quantitative PCR May be a Useful Tool for Monitoring Minimal Residual Disease in B-Cell ALL. Blood, 2021, 138, 3998-3998.	1.4	0
263	Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes. Blood, 2020, 136, 42-43.	1.4	0
264	Development and Validation of a Prognostic Model for Transplant-Associated Thrombotic Microangiopathy Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 16-17.	1.4	0
265	Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR+ and Î±vÎ²3+ Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT. Blood, 2020, 136, 25-25.	1.4	0
266	Risk and Prognostic Factors for Intracranial Hemorrhage in Elderly Patients with Immune Thrombocytopenia. Blood, 2020, 136, 14-15.	1.4	0